Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 6, 2003, Pages 678-682

  Komazawa, Yoshinori ^a   Adachi, Kyoichi ^a   Mihara, Takafumi ^a   Ono, Masahiro ^a   Kawamura, Akira ^a   Fujishiro, Hirofumi ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Famotidine; pH monitoring; Ranitidine; Tolerance

Indexed keywords

FAMOTIDINE; GASTRIN; HISTAMINE H2 RECEPTOR; RANITIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG TOLERANCE; GASTRIN BLOOD LEVEL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; LONG TERM CARE; MALE; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH;

EID: 0038727629     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.03041.x     Document Type: Article

References (30)

1. Howden CW. Potent versus mild acid suppression in peptic ulcer disease. Hepatogastroenterology 1992; 39: 45-6.
2. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987; 28: 1120-7.
3. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am. J. Gastroenterol. 1999; 94: 1434-42.
4. Jansen JB, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. Aliment. Pharmacol. Ther. 1999; 13: 1611-20.
5. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment. Pharmacol. Ther. 1994; 8: 193-201.
6. Wilder-Smith C, Halter F, Ernst T et al. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment. Pharmacol. Ther. 1990; 4 (Suppl. 1): 15-27.
7. Smith JT, Gavey C, Nwokolo CU, Pounder RE. Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. Aliment. Pharmacol. Ther. 1990; 4 (Suppl. 1): 47-63.
8. Nwokolo CU, Smith JT, Gavey C, Sawyerr A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment. Pharmacol. Ther. 1990; 4 (Suppl. 1): S29-45.
9. Labenz J, Peitz U, Leusing C, Tillenburg B, Blum AL, Borsch G. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Gut 1997; 40: 36-41.
10. Netzer P, Gaia C, Sandoz M et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am. J. Gastroenterol. 1999; 94: 351-7.
11. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994; 106: 60-4.
12. Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion - tolerance and rebound. Aliment. Pharmacol. Ther. 1997; 11: 1013-18.
13. Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am. J. Gastroenterol. 2000; 95: 57-61.
14. Savarino V, Mela GS, Scalabrini P, Di Timoteo E, Magnolia MR, Celle G. Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer. Digestion 1987; 37: 103-9.
15. Schunack W. What are the differences between the H2-receptor antagonists? Aliment. Pharmacol. Ther. 1987; 1 (Suppl.): 493S-503S.
16. Howard JM, Chremos AN, Collen MJ et al. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 1985; 88: 1026-33.
17. Reilly TG, Singh S, Cottrell J, Mann SG, Stauffer L, Walt RP. Low-dose famotidine and ranitidine as single postprandial doses: a three-period placebo-controlled comparative trial. Aliment. Pharmacol. Ther. 1996; 10: 749-55.
18. Al-Quorain A, Ammar A, Al-Awami M et al. Comparison of intravenous famotidine and ranitidine in suppressing gastric acid secretion in critically ill patients. Current Therapeutic Res. 1994; 55: 1263-70.
19. Wong CF, Peh KK, Yuen KH. Simple high-performance liquid chromatographic method for the determination of ranitidine in human plasma. J. Chromatogr. B. Biomed. Sci. Appl. 1998; 718: 205-10.
20. Imai Y, Kobayashi S. A simple method for the quantification of famotidine in human plasma and urine by paired-ion high performance liquid chromatography. Biomed. Chromatogr. 1992; 6: 222-3.
21. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-16.
22. Labenz J, Tillenburg B, Peitz U et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
23. Hirschowitz BI, Keeling D, Lewin M et al. Pharmacological aspects of acid secretion. Dig. Dis. Sci. 1995; 40 (Suppl.): 3S-23S.
24. Scott DR, Besancon M, Sachs G, Helander H. Effects of antisecretory agents on parietal cell structure and H/K-ATPase levels in rabbit gastric mucosa in vivo. Dig. Dis. Sci. 1994; 39: 2118-26.
25. Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract. Res. Clin. Gastroenterol. 2001; 15: 487-95.
26. Brand SJ, Stone D. Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria. J. Clin. Invest. 1988; 82: 1059-66.
27. Simon TJ, Roberts WG, Berlin RG, Hayden LJ, Berman RS, Reagan JE. Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis. Clin. Ther. 1995; 17: 1147-56.
28. Wesdorp IC. Famotidine in gastroesophageal reflux disease (GERD). Hepatogastroenterology 1992; 39 (Suppl. 1): 24-6.
29. Berlin RG, Root JK, Cook TJ. Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer. Aliment. Pharmacol. Ther. 1991; 5: 161-71.
30. Bianchi Porto G, Lazzaroni M, Barbara L et al. A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. Aliment. Pharmacol. Ther. 1991; 5: 181-9.